Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOEP-14 + rituximab with CNS prophylaxis in high-risk DLBCL/follicular lymphoma grade III
2004-003075-37Phase 2Completed
- Sponsor
- Nordic Lymphoma Group
- Start
- Sep 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Nordic Lymphoma Group. Primary endpoint: Time to treatment failure. Started Sep 2004; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2004-003075-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003075-37.